BRCA2 and neoplasm: Patients whose tumours had low levels of expression of BRCA2 with high levels of MRE11 co-expression (Figure 5E) had worse PFS (p = 0.005, Figure 5F) and overall survival (p = 0.001, Figure 5G) compared to patients whose tumours had high levels of BRCA2 with low levels of MRE11 co-expression.